Briefing
Longitudinal detection of circulating tumor DNA in patients with advanced renal cell carcinoma.
ctDNA was detected at any time point in 70% (29/41). All 14 patients who progressed had ctDNA detected ahead of radiographic progression (100% sensitivity in this series) with a median lead time of 13.6 weeks (range 1-39.7). Concordance between clinical outcome and ctDNA status was 78% (32/41).
- n: 41 patients with advanced RCC
- Assay: Signatera (tumor-informed)